Predictive Factors for the Therapeutic Response to Concomitant Treatment with DPP-4 Inhibitors in Type 2 Diabetes with Short-Term Follow-Up.
10.7180/kmj.2016.31.2.146
- Author:
Jong Ha BAEK
1
;
Bo Ra KIM
;
Jeong Woo HONG
;
Soo Kyoung KIM
;
Jung Hwa JUNG
;
Jaehoon JUNG
;
Jong Ryeal HAHM
Author Information
1. Department of Internal Medicine, Gyeongsang National University Hospital, Jinju-si, Gyeongsangnam-do, Korea. jrhahm@gnu.ac.kr
- Publication Type:Original Article
- Keywords:
Dipeptidyl peptidase-4 inhibitor;
efficacy;
predictive factor;
type 2 diabetes mellitus
- MeSH:
Blood Glucose;
Diabetes Mellitus, Type 2;
Fasting;
Follow-Up Studies*;
Humans;
Hypoglycemic Agents;
Insulin;
Insulins;
Retrospective Studies
- From:Kosin Medical Journal
2016;31(2):146-156
- CountryRepublic of Korea
- Language:English
-
Abstract:
OBJECTIVES: To evaluate the efficacy and predictive factors of Dipeptidyl peptidase-4 (DPP-4) inhibitors in type 2 diabetes mellitus (T2DM) patients who were not well controlled with other oral antidiabetic drugs or insulin in real clinical practice. METHODS: From December 2012 to January 2014, retrospective longitudinal observation study was conducted for patients with T2DM who were not reached a glycemic target (glycated hemoglobin [HbA1c] > 6.5%) with other oral antidiabetic drugs or insulins. Type 1 diabetes or other types of diabetes were excluded. Responders were eligible with decreased HbA1c from baseline for more than 5% during follow up period. RESULTS: Of total 135 T2DM patients having an average 9.0 months follow-up period, 84 (62.2%) of patients were responder to DPP-4 inhibitors. After concomitant treatment with DPP-4 inhibitors, patients had a mean decrease in HbA1c of 0.69 ± 1.3%, fasting plasma glucose of 13 ± 52 mg/㎗, and postprandial plasma glucose of 29 ± 85 mg/㎗ from baseline (all P < 0.05). Independent predictive factor for an improvement of glycemic control with DPP-4 inhibitors was higher baseline HbA1c (odds ratio 2.07 with 95% confidence interval 1.15-3.72) compared with non-responders. CONCLUSIONS: A clinical meaningful improvement in glycemic control was seen when DPP-4 inhibitors were added to other anti-diabetic medications in patients with T2DM regardless of age, duration of T2DM, type of combination treatment regimen. Patients who had higher HbA1c were more easily respond to DPP-4 inhibitors treatment in short-term follow-up period.
